Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised …
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-04-17 10:22:16 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
EL Simpson, R Sinclair, S Forman, A Wollenberg…
The Lancet, 2020
thelancet.com
Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis. Methods In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged≥ 12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score≥ 3, Eczema Area and Severity Index …
